Geoffrey Thomas Gibney, MD, MedStar Georgetown University Hospital

home / authors / geoffrey-thomas-gibney-md-medstar-georgetown-university-hospital

Articles

Geoffrey T. Gibney, MD

Dr. Gibney on the Potential for Fixed-Duration Immunotherapy in Melanoma

Geoffrey Thomas Gibney, MD, MedStar Georgetown University Hospital
March 19th 2021

Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.

Read More

Geoffrey T. Gibney, MD

Dr. Gibney on Determining Optimal Treatment Duration With Anti–PD-1 Agents in Melanoma

Geoffrey Thomas Gibney, MD, MedStar Georgetown University Hospital
February 26th 2021

Geoffrey T. Gibney, MD, discusses efforts made to determine the optimal duration of treatment with anti–PD-1 agents in patients with melanoma.

Read More

Geoffrey T. Gibney, MD, of the Lombardi Comprehensive Cancer Center

Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma

Geoffrey Thomas Gibney, MD, MedStar Georgetown University Hospital
November 2nd 2020

Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data